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Dean Baker and Adriane Fugh-Berman have published a critique of a study I performed in 
2007, entitled “Why has longevity increased more in some states than in others?” One of the 
conclusions I drew from that study was that medical innovation accounts for a substantial 
portion of recent increases in U.S. life expectancy. Baker and Fugh-Berman claim that my 
study was subject to a number of major methodological flaws. Many of their claims pertain to 
the role of infant mortality; the definition of drug vintage; the issue of age adjustment; and the 
appropriateness of controlling for AIDS, obesity, and smoking in the analysis of longevity. In 
this article, I make the case that their claims about my study are largely incorrect. I show that 
infant mortality was not an important determinant of the growth in U.S. life expectancy 
during the period that I studied, and that my estimates are completely insensitive to the 
inclusion or exclusion of infant mortality. Controlling for the age distribution of the 
population also has essentially no effect on the longevity equation estimates. I argue that my 
definition of drug vintage, based on the initial FDA approval year of a drug’s active 
ingredient, is quite reasonable, and it is consistent with the FDA’s evaluation of the 
therapeutic potential of new drugs. I argue that controlling for AIDS, obesity, and smoking in 
longevity analysis is entirely appropriate and consistent with the epidemiological literature. 
Baker and Fugh-Berman express deep skepticism about my study’s conclusion that medical 
innovation has played a very important role in recent U.S. longevity growth, but they offer no 
explanation of why life expectancy increased by almost a year during 2000-2006, a period of 
increasing poverty and obesity and declining health insurance coverage. 
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Dean Baker and Adriane Fugh-Berman (2009) have published a critique of a 
study (Lichtenberg (2007)) I performed in 2007, entitled “Why has longevity increased 
more in some states than in others?”  One of the conclusions I drew from that study was 
that medical innovation accounts for a substantial portion of the recent increase in U.S. 
life expectancy.  Baker and Fugh-Berman claim that my study was subject to a number of 
major methodological flaws.  Many of their claims pertain to the role of infant mortality; 
the definition of drug vintage; the issue of age adjustment; and the appropriateness of 
controlling for AIDS, obesity, and smoking in the analysis of longevity.  In this article, I 




Baker and Fugh-Berman make several misleading or incorrect claims related to 
infant mortality.  First, they claimed that my study “fail[ed] to control for infant 
mortality.”    However, one of the measures I examined was life expectancy at birth, 
which depends on the mortality rate of infants as well as the mortality rate of older 
individuals.
1   
Baker and Fugh-Berman also claim that “infant mortality is the single most 
important determinant of life expectancy.”  Infant mortality was not the most important 
determinant of the growth in U.S. life expectancy during the period that I studied.  Data 
from the National Center for Health Statistics indicate that between 1989-1991 and 2002, 
life expectancy at birth increased 1.93 years, and life expectancy at age 1 increased by 
1.72 years.
2  Only 11% of the increase in life expectancy at birth was due to a reduction 
                                           
1 Baker and Fugh-Berman’s Figure 1 shows the relationship across states between infant mortality rates and 
life expectancy at birth in the United States.  It is unusual to show a correlation between a variable X and 
another variable which is calculated using X.  Also, the data shown in their Figure 1 (which shows the 
correlation across states between the level of life expectancy and the level of the infant mortality rate) are 
irrelevant to my argument.  My study sought to explain interstate variation in the growth in life expectancy, 
not the level of life expectancy.  Baker and Fugh-Berman fail to distinguish between the level and the 
growth of life expectancy.   
2  
Life expectancy  1989-1991  2002  change 
At birth  75.37  77.3  1.93 
At age 1  75.08  76.8  1.72 
Source: Arias (2004, Table 11)   3
in infant mortality.
3  Their claim that “disparities in [infant mortality rates] could account 
for most differences in longevity in Lichtenberg’s analysis” is incorrect.
4 
The sensitivity of my results to infant mortality can easily be assessed by 
changing the dependent variable in eq. (1) of my study from life expectancy at birth to 
life expectancy at age 1 or higher ages. The results of this sensitivity analysis are shown 
in columns 1-3 of Table 1.  In column 1 the dependent variable is life expectancy at birth.  
This is essentially the same equation as the one shown in column 1 of Table 6 of 
Lichtenberg (2007).
5  In column 2 the dependent variable is life expectancy at age 1, and 
in column 3 the dependent variable is life expectancy at age 20.  The regression 
coefficients in all three of these equations are almost identical.  The estimates are 
completely insensitive to the inclusion or exclusion of infant mortality. 
    
Measurement of vintage 
 
I defined the vintage of a (single-ingredient) drug as the year in which the drug’s 
active ingredient was first approved by the FDA.
6  All formulations of a drug with the 
same active ingredient are defined as having the same vintage, even though some 
formulations may have received FDA approval later than others.  Baker and Fugh-
Berman seem to think that this way of defining vintage is arbitrary or peculiar.  However 
this way of defining vintage is quite consistent with the FDA’s way of classifying new 
drugs according to their “therapeutic potential.” 
The FDA classifies all new drug applications as either priority-review or 
standard-review applications.  A Priority Review designation is given to drugs that are 
expected to offer major advances in treatment, or provide a treatment where no adequate 
                                           
3 As shown in Table 4 of the MI paper, during the period 1991-2004, the increase in life expectancy at age 
65 was 57% as large as the increase in life expectancy at birth 
4 I acknowledged in my paper that “differences in drug vintage explain some of the interstate variation in 
life expectancy, but the fraction of cross-sectional variance explained is smaller than the fraction of 
aggregate time-series variance (growth) explained.” 
5 The estimates reported in Table 1 allow for clustered standard errors.  The estimates reported in Table 6 of 
Lichtenberg (2007) did not allow for clustering. 
6 The vintage of a combination drug is the mean of the years in which the drug’s active ingredients were 
first approved by the FDA.   4
therapy exists.  Standard Review is applied to a drug that is expected to offer at most, 
only minor improvement over existing marketed therapies.
7   
As shown in the following table, based on new drug approvals during the period 
1990-2004, new molecular entities were three times as likely to provide significant 
improvements compared to marketed products in the treatment, diagnosis, or prevention 
of a disease as new formulations.   
 
   New molecular entities  New formulations 
Priority review  183  86 
Standard review  248  524 
% Priority review  42%  14% 
It is therefore quite reasonable, and consistent with FDA evaluation of the therapeutic 
potential of new drugs, to define the vintage of a drug as the year in which the drug’s 
active ingredient was first approved. 
AIDS, obesity, and smoking 
 
The models that I estimated adjusted for AIDS, obesity, and smoking. Baker and 
Fugh-Berman were critical of this.  They argued that this was “an unusual set of 
variables.” 
Baker and Fugh-Berman argued that “AIDS is not among the 15 leading causes of 
death in any state in the U.S., so has a dubious role in this type of analysis.”  By that 
standard, infant mortality also has a dubious role: in 1995 (near the peak of the U.S. 
AIDS epidemic), the number of deaths from HIV/AIDS was 43% larger than the number 
of infant deaths (42,337 vs. 29,583).  
However, that is not a reasonable standard.  The effect of a disease on life 
expectancy depends on the age at which people die from the disease as well as on the 
frequency of the disease.  According to the CDC, the median age at death due to HIV 
disease in 1995—just before antiretroviral drugs were introduced—was 39 years.  
Consequently, HIV was the fourth largest cause of years of potential life lost (YPLL) 
                                           
7 Unfortunately, when a drug is designated a standard-review drug, the FDA does not identify the 
previously-approved drug(s) to which that drug is considered equivalent.   5
before age 65 in 1995.  The first three were unintentional injuries, cancer, and heart 
disease.  Lichtenberg ( ) provides evidence that pharmaceutical innovation has increased 
cancer survival rates and reduced age-adjusted cardiovascular mortality rates. 
Baker and Fugh-Berman also claimed that “obesity and smoking are risk factors 
for numerous diseases, but are not acceptable surrogate markers for causes of death.”  But 
the CDC has performed studies to estimate mortality attributable to both obesity and 
smoking.  CDC senior epidemiologist Katherine Flegal et al (2005) estimated deaths 
associated with underweight
 (body mass index [BMI] <18.5), overweight (BMI 25 to 
<30),
 and obesity (BMI  30) in the United States in 2000.  They found that “underweight 
and obesity, particularly higher
 levels of obesity, were associated with increased mortality
 
relative to the normal weight category.”  CDC (2005) also calculates national estimates of 
annual smoking-attributable mortality (SAM) and years of potential life lost (YPLL) for 
adults and infants. It estimates that, during 1997-2001, cigarette smoking and exposure to 
tobacco smoke resulted in approximately 438,000 premature deaths in the United States 
and 5.5 million YPLL. 
 
Controlling for population age 
 
Baker and Fugh-Berman claimed that my “analysis [did] not control for age.”  
This claim is not entirely accurate.  Also, I will show that controlling for age does not 
change the basic conclusions. 
The most important dependent variable in my study—life expectancy—is based 
on age-specific mortality rates: it controls for (is not affected by) the age distribution of 
the population. 
Drugs in different therapeutic classes tend to be used by different age groups.  For 
example, cardiovascular and cancer drugs tend to be used disproportionately by older 
people.  Some of the models I estimated included a fixed-weight index of drug vintage, 
rather than a standard (crude) index of drug vintage.  The fixed-weight vintage index 
controls for (holds constant) the distribution of drugs by therapeutic class, which is 
somewhat correlated with the distribution of drugs by age of user.   6
The potential bias in my estimates from failure to control for age can be assessed 
by including a measure of the age distribution in the longevity equation.
8  The equation 
shown in column 4 of Table 1 includes the fraction of the population that is age 65 or 
over (old%) as a covariate.
9   The coefficient on this variable is positive but statistically 
insignificant.  Controlling for the age distribution of the population has essentially no 
effect on the other coefficients. 
 
Income, education, and longevity 
 
  Many studies have found a positive correlation between (the level of) 
socioeconomic status (income or education) and (the level of) life expectancy.  Baker and 
Fugh-Berman argue that the absence of a positive correlation across states between 
changes in income or education and longevity growth proves that my model is 
misspecified.  However, there is good reason to believe that cross-sectional correlations 
between longevity and either income or education substantially overestimate the effect of 
socioeconomic status per se on longevity.  For example, the positive correlation between 
income and longevity may reflect the effect of health on income (“reverse causality”) as 
well as the effect of income on health.   
Similarly, Almond and Mazumder (2006) argue that, “although it is well known 
that there is a strong association between education and health, much less is known about 
how these factors are connected, and whether the relationship is causal.”  Lleras-Muney 
(2005) provided perhaps the strongest evidence that education has a causal effect on 
health. Using state compulsory school laws as instruments, Lleras-Muney found large 
effects of education on mortality. Almond and Mazumder (2006) revisited these results, 
noting they are not robust to state time trends, even when the sample is vastly expanded 
and a coding error rectified. They employed a dataset containing a broad array of health 
outcomes and found that when using the same instruments, the pattern of effects for 
specific health conditions appears to depart markedly from prominent theories of how 
                                           
8 However, controlling for age in this manner runs the risk of underestimating the longevity gains from 
pharmaceutical innovation.  If the causal mechanism is drug vintage  life expectancy  population age, 
holding population age constant could bias estimates of the effect of drug vintage on life expectancy 
downward. 
9 The elderly account for about 13% of the U.S. population and about a third of U.S. pharmaceutical use.   7
education should affect health. They also found suggestive evidence that vaccination 
against smallpox for school age children may account for some of the improvement in 
health and its association with education. This raised concerns about using compulsory 
schooling laws to identify the causal effects of education on health.  
 
Where do longevity gains come from? 
 
  Baker and Fugh-Berman express deep skepticism about my study’s conclusion 
that medical innovation has played a very important role in recent U.S. longevity growth.  
How, then, would they account for the U.S. experience during the period 2000-2006?  
During that period, the poverty rate increased from 11.3% to 12.3%, median real 
household income declined about 2%, the share of Americans without health insurance 
increased from 13.7% to 15.8%, the fraction of Americans who were overweight or obese 
increased from 56.9% to 61.8%
10--and life expectancy at birth increased by 0.9 years, 
from 76.8 to 77.7.
11   
Educational attainment also increased:
12 the fraction of adults who had attended at 
least some college increased from 51.0% in 2000 to 53.7% in 2006.
13  But the most 
recent (and largest) estimates of education-related longevity differences, which for 
reasons discussed above are likely to overstate the effect of education on longevity, imply 
that increased educational attainment would have increased U.S. life expectancy by only 
0.10-0.19 years during the period 2000-2006.
14  Baker and Fugh-Berman offer no 
explanation of why life expectancy increased so much more than that, during a period of 
increasing poverty and obesity and declining health insurance coverage. 
                                           
10 Source: Bernstein 
11 Source: Heron 
12  There was also a modest decline in smoking during that period: the fraction of adults who smoked was 
22.7% in 1995, 23.2% in 2000, and 20.1% in 2006.  Source: BRFSS. 
13 Source: Table A-1. Years of School Completed by People 25 Years and Over, by Age and Sex:  Selected 
Years 1940 to 2008 
14 Meara et al (2008) report that data from the National Longitudinal Mortality Study imply that, during the 
period 1991-1998, life expectancy at age 25 of people with any college education was 3.7 years higher than 
that of people with no college education.  Data from Multiple Cause of Death files and census data imply 
that, in the year 2000, life expectancy at age 25 of people with any college education was 7.0 years higher 
than that of people with no college education   8
Summary 
Dean Baker and Adriane Fugh-Berman have published a critique of a study I 
performed in 2007, entitled “Why has longevity increased more in some states than in 
others?”  One of the conclusions I drew from that study was that medical innovation 
accounts for a substantial portion of recent increases in U.S. life expectancy.  Baker and 
Fugh-Berman claim that my study was subject to a number of major methodological 
flaws.  Many of their claims pertain to the role of infant mortality; the definition of drug 
vintage; the issue of age adjustment; and the appropriateness of controlling for AIDS, 
obesity, and smoking in the analysis of longevity.  In this article, I made the case that 
their claims about my study are largely incorrect.
15 
I showed that infant mortality was not an important determinant of the growth in 
U.S. life expectancy during the period that I studied, and that my estimates are 
completely insensitive to the inclusion or exclusion of infant mortality.  Controlling for 
the age distribution of the population also has essentially no effect on the longevity 
equation estimates. 
  I argued that my definition of drug vintage, based on the initial FDA approval 
year of a drug’s active ingredient, is quite reasonable, and it is consistent with the FDA’s 
evaluation of the therapeutic potential of new drugs. 
  I argued that controlling for AIDS, obesity, and smoking in longevity analysis is 
entirely appropriate and consistent with the epidemiological literature. 
Baker and Fugh-Berman express deep skepticism about my study’s conclusion 
that medical innovation has played a very important role in recent U.S. longevity growth, 
but they offer no explanation of why life expectancy increased by almost a year during 
2000-2006, a period of increasing poverty and obesity and declining health insurance 
coverage. 
                                           
15 Their article contains other incorrect statements.  I did not use 2004 payment information from state 
Medicaid programs and Medicare to calculate the rate of adoption of new prescription drugs in each state.  
Also, almost all of my studies have appeared or are forthcoming in peer-reviewed journals and books, not 
only as working papers.   9
References 
Almond, Douglas, and Bhashkar Mazumder (2006), “How did schooling laws improve 
long-term health and lower mortality?,” Federal Reserve Bank of Chicago Working Paper 
No WP-06-23, http://www.chicagofed.org/publications/workingpapers/wp2006_23.pdf  
Arias E. United States life tables, 2002. National vital statistics reports; vol 53 no 6. 
Hyattsville, Maryland: National Center for Health Statistics. 2004, Table 11, 
http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_06.pdf 
 
Baker, Dean, and Adriane Fugh-Berman (2009), “Do New Drugs Increase Life 
Expectancy? A Critique of a Manhattan Institute Paper,” Journal of General Internal 
Medicine 
Bernstein, Jared (2007), “Income Picture,” August 28, 
http://www.epi.org/publications/entry/webfeatures_econindicators_income20070828/  
CDC, BRFSS Prevalence and Trends data, http://apps.nccd.cdc.gov/brfss/  
CDC (2005), “Annual Smoking-Attributable Mortality, Years of Potential Life Lost, and 
Productivity Losses --- United States, 1997—2001,” Morbidity and Mortality Weekly 
Report 54(25);625-628, July 1, 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5425a1.htm  
CDC, HIV Mortality Slides, 
http://www.cdc.gov/hiv/topics/surveillance/resources/slides/mortality/index.htm  
 
CDC, WISQARS Years of Potential Life Lost (YPLL) Reports, 1981-1998, 
http://webappa.cdc.gov/sasweb/ncipc/ypll9.html  
 
Flegal, Katherine M., et al (2005), “Excess Deaths Associated with Underweight, 
Overweight, and Obesity,” JAMA 293:1861-1867, http://jama.ama-
assn.org/cgi/content/full/293/15/1861  
FDA, NDA Approvals by Therapeutic Potential and Chemical Type, 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAp
proved/DrugandBiologicApprovalReports/ucm121102.htm  
FDA, Fast Track, Accelerated Approval and Priority Review, 
http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccesstoI
mportantNewTherapies/ucm128291.htm  
Heron MP, et al (2009). Deaths: Final data for 2006. National vital statistics reports; vol 
57 no 14. Hyattsville, Maryland: National Center for Health Statistics. 2009. 
http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf  
   10
Lichtenberg, Frank (2007), “Why Has Longevity Increased More in Some States than in 
Others? The Role of Medical Innovation and Other Factors.”  New York: Manhattan 
Institute. http://www.manhattan-institute.org/html/mpr_04.htm  
 
Lichtenberg, Frank “Have newer cardiovascular drugs reduced hospitalization?  Evidence 
from longitudinal country-level data on 20 OECD countries, 1995-2003,” Health 
Economics, http://www3.interscience.wiley.com/journal/120750818/abstract 
 
Lichtenberg, Frank "Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: 
Evidence from Linked SEER-MEDSTAT Data," Forum for Health Economics & Policy: 
Vol. 10: Iss. 1 (Frontiers in Health Policy Research), Article 1. 
http://www.bepress.com/fhep/10/1/1  
 
Lichtenberg, Frank “The effect of new cancer drug approvals on the life expectancy of 
American cancer patients, 1978-2004,” Economics of Innovation and New Technology, 
forthcoming. 
 
Lichtenberg, Frank “International differences in cancer survival rates: the role of new 
drug launches,” International Journal of Healthcare Technology and Management, 
forthcoming. 
 
Lleras-Muney, A. (2005), “The relationship between education and adult mortality in the 
United States,” Review of Economic Studies 72 (1), 189-221.  
 
Meara, Ellen R., Seth Richards, and David M. Cutler (2008), “The Gap Gets Bigger: 
Changes In Mortality and Life Expectancy, By Education, 1981–2000,” Health Affairs, 
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Z -2.089 -2.094 -2.114 -2.137
ProbZ 0.037 0.036 0.034 0.033
now_smoke -2.149 -2.369 -2.507 -2.198
Z -1.253 -1.444 -1.613 -1.265
ProbZ 0.210 0.149 0.107 0.206
edu 0.026 -0.042 0.001 0.020
Z 0.097 -0.158 0.005 0.077
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health_cov 0.461 0.403 0.284 0.315
Z 0.372 0.350 0.251 0.252
ProbZ 0.710 0.726 0.802 0.801
income -1.346 -1.410 -1.174 -1.220
Z -1.169 -1.297 -1.045 -1.055
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